CD274 and non-small cell lung carcinoma: Moreover, the NCCN guidelines for NSCLC indicated that atezolizumab and pembrolizumab, as immunotherapy, showed excellent efficacy for programmed cell death ligand 1 (PD-L1) ≥1% and PD-L1 ≥50%, respectively.